CRISPR Therapeutics AG (NASDAQ:CRSP) price closed lower on Tuesday,December 03, and dropping -7.09% below its previous close.
A look at the daily price movement shows that the last close reads $55.15, with intraday deals fluctuated between $51.2 and $54.5499. The company’s 5Y monthly beta was ticking 1.662. Taking into account the 52-week price action we note that the stock hit a 52-week high of $91.10 and 52-week low of $43.42. The stock added 0.95% on its value in the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRISPR Therapeutics AG, which has a market valuation of $4.37 billion, is expected to release its quarterly earnings report in January.
The average estimate suggests sales growth for the quarter will likely fall by -96.33% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of 14.39M for the company’s annual revenue in current year. Per this projection, the revenue is forecast to grow -96.12% below that which the company brought in the current year earning report.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give CRSP a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 8 analysts have assigned CRSP a recommendation rating as follows: 2 rate it as a Hold; 6 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the CRISPR Therapeutics AG (CRSP) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that CRSP’s price is at present 2.70% off the SMA20 and 6.06% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 54.12, with weekly volatility standing at 5.09%. The indicator jumps to 5.22% when calculated based on the past 30 days. CRISPR Therapeutics AG (NASDAQ:CRSP)’s beta value is holding at 1.63, while the average true range (ATR) indicator is currently reading 2.55. Considering analysts have assigned the stock a price target range of $52-$180 as the low and high respectively, we find the trailing 12-month average consensus price target to be $89.5. Based on this estimate, we see that current price is roughly -1.48% off the estimated low and -251.29% off the forecast high. Investors will no doubt be excited to see the share price fall to $89.5, which is the median consensus price, and at that level CRSP would be -74.67% from current price.
An analysis of the CRISPR Therapeutics AG (NASDAQ:CRSP) stock in terms of its daily trading volume indicates that the 3-month average is 1.37 million. However, this figure increases on the past 10-day timeline to an average of 1.8 million.
Current records show that the company has 85.34M in outstanding shares. The percentage share held by institutions stands at 67.62%. The stats also highlight that short interest as of 2024-11-15, stood at 19.39 million shares, which puts the short ratio at the time at 11.99. From this we can glean that short interest is 2575.00 of company’s current outstanding shares. Notably, we see that shares short in November rose slightly given the previous month’s figure stood at 17.59 million. But the -18.15% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
